miR-145-5p Inhibits HER2-Positive Breast Cancer Cells via Targeting ARF6

Lixian Yang1, Wei Dang2, Fanting Kong1

  • 1Department of Breast Surgery, Xingtai People's Hospital, Xingtai, Hebei Province, 054000, People's Republic of China.

Abstract

Insights

MicroRNA-145-5p (miR-145-5p) inhibits breast cancer growth and spread by targeting the ADP-ribosylation factor 6 (ARF6) gene. This discovery offers a potential new avenue for breast cancer diagnosis and treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Breast cancer is a significant global health concern with complex molecular underpinnings.
  • MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
  • Understanding specific miRNA functions, like that of miR-145-5p, is vital for therapeutic advancements.

Purpose of the Study:

  • To investigate the role of miR-145-5p in inhibiting breast cancer cell growth and migration.
  • To identify the target gene, ADP-ribosylation factor 6 (ARF6), modulated by miR-145-5p.
  • To elucidate the underlying molecular mechanisms of miR-145-5p action in breast cancer.

Main Methods:

  • Bioinformatic analysis of miR-145-5p expression in breast cancer using TCGA database.
  • Quantitative reverse transcription PCR (RT-qPCR) on clinical samples and cell lines.
  • In vitro assays (CCK-8, scratch, Transwell) to assess cell viability, migration, and invasion upon miR-145-5p manipulation.
  • Dual-luciferase reporter assay to confirm direct interaction between miR-145-5p and ARF6 mRNA.

Main Results:

  • miR-145-5p expression was significantly reduced in breast cancer tissues, particularly in HER2-positive cases.
  • Overexpression of miR-145-5p suppressed breast cancer cell proliferation, migration, and invasion.
  • miR-145-5p directly targets the 3'-untranslated region of ARF6 mRNA, inhibiting its expression.

Conclusions:

  • miR-145-5p acts as a tumor suppressor in breast cancer by inhibiting proliferation, migration, and invasion via ARF6 targeting.
  • The miR-145-5p/ARF6 axis represents a potential novel therapeutic target for breast cancer.
  • This miRNA holds promise for accurate diagnosis and effective treatment strategies for breast cancer patients.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K